Kapspargo Sprinkle generic
Kapspargo Sprinkle is an extended-release oral drug, containing metoprolol succinate, which is owned by Spil. The medication was authorized for market use on 26 January, 2018.
When will Kapspargo Sprinkle generic be available?
The generic versions of Kapspargo Sprinkle may become available after 09 July, 2035. This is because the last active patent, pertaining to a capsule dosage form of Metoprolol Succinate, expires on this date. Any generic release prior to that would require a successful Para IV filing.
Kapspargo Sprinkle uses
Kapspargo Sprinkle, with its active ingredient metoprolol succinate, is primarily used for treating hypertension, angina, and heart failure. Its extended release formula ensures the continuous delivery of the drug, thereby helping manage these conditions more effectively.
Kapspargo Sprinkle patent expiration
Kapspargo Sprinkle is backed by two patents, none of which have expired. The last patent, related to its capsule dosage form, expires on 09 July, 2035. Below are the details of the patent: